TCBP

TC Biopharm (Holdings) Plc (TCBP) | Rumor.io

TC Biopharm (Holdings)

TCBP

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)98%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about TCBP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Apr 20

TCBP has seen a significant decline of -100.94%.
There is speculation about the possibility of TCBP being delisted due to multiple stock splits in a short period.
The company's leadership is being criticized for prioritizing profits over regulatory compliance.

Generated by AI

Sentiment

Of the messages about TCBP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	54.62% -22.66
Bearish	—	—	0% 0	45.38% +22.66

Bullish· Mar 21

The short squeeze in TCBP is likely to continue due to a high short interest ratio of 128.04K shares short on 734K outstanding.
TCBP's technology has shown promise in treating relapsed refractory AML, with the majority of participants in the Achieve 2/3 b UK trial alive beyond their life expectancy, making it a potential game-changer in the medical field.
The company's acquisition of an eye drop company with $8 billion in revenue and two more acquisitions to close this year could lead to significant growth and revenue increases for TCBP.

Bearish· Mar 21

$TCBP has lost a significant amount of value, down $680,000 since its IPO.
The company's financial situation is precarious, with the asset value potentially amounting to only £1,645 upon bankruptcy.
Misleading statements made by the CEO, including claims that the company was not in danger of delisting, could lead to legal claims and potentially result in the company going bankrupt.

Generated by AI

Topics

Of the messages about TCBP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	0%
Announcements	—	—	100%	83.53%
Controversies	—	—	0%	9.41%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	7.06%

Analysts· Jan 27

Analyst firm HC Wainwright & Co. initiated coverage on TC BioPharm (Holdings) with a Buy rating and a price target of $9.
The latest price target for TC BioPharm (Holdings) is $9, expecting a 57.89% upside within 12 months, according to HC Wainwright & Co.
7 analysts have analyzed TC BioPharm, with a consensus buy rating of 83%, indicating analysts are confident in the stock.

Announcements· May 6

TC BioPharm has announced the exercise of warrants for £3.1 million in gross proceeds, providing a much-needed financial boost to the company.
The company has executed a second non-binding letter of intent for the acquisition of a privately-held biotech company specializing in CAR-T therapies, potentially expanding its treatment options and therapeutic potential.
TC BioPharm's innovative gamma-delta T cell therapies have demonstrated proof of concept data for the treatment of multiple solid tumors, positioning the company as a potential acquisition target in the biotech industry.

Technical Analysis· May 6

$TCBP has been showing a strong uptrend with higher lows and higher highs in its 3-month chart.
The stock's price is expected to reach $3.30, $3.52, or potentially $4.15, with a stop loss at $2.87.
$TCBP's price is above its volume-weighted average price (VWAP), with a key zone to watch being $3.3-$3.5.

Generated by AI

Community

Of the messages about TCBP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	53.97%
Newcomers	—	—	0%	46.03%

Regulars· Dec 18

TC BioPharm's Board of Directors approved a special dividend of 0.25 ADS for every 1 ADS held by shareholders, pending shareholder approval.
The company intends to hold a general meeting of shareholders on Monday to discuss the dividend and other matters.
The special dividend is seen as a positive development, with the stock price experiencing a significant increase, and the regulars are keeping a close eye on the stock's performance.

Newcomers· Dec 18

Many newcomers are interested in TC Biopharm (Holdings) Plc due to its significant price increase, with some gains exceeding 177%.
The company's announcement of a special dividend has drawn attention, with some investors seeing it as a positive development for the company.
New traders are also looking at TC Biopharm's technical levels, such as support and resistance points, as they try to gauge the stock's potential movement in the pre-market session.

Generated by AI

Also Discussed

Investors talking about TCBP also mention

#	Name	Attention
1	SMFL - Smart for Life, Inc.	——
2	PBLA - Panbela Therapeutics, Inc.	——
3	HeartSciences Inc.HSCS	0%0
4	Allarity Therapeutics Inc.ALLR	0%-0.01
5	ZVSA - ZyVersa Therapeutics, Inc.	——
6	MINM - Minim, Inc.	——
7	LVTX - LAVA Therapeutics N.V.	——
8	MGAM - Mobile Global Esports Inc.	——
9	noco-noco Inc.NCNC	0%0
10	Elutia Inc. Class A Common StockELUT	0%new